Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04570839 · ClinicalTrials.gov registry record · Phase 1
COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.
A Phase 1 study, sponsored by Compugen.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT04570839 is a Phase 1 study that has completed, run by Compugen. The registered enrollment target is 48 participants.
The verdict
NCT04570839, a Phase 1 study, has completed, sponsored by Compugen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This is a phase 1/2 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM701 in combination with BMS-986207 and nivolumab in patients with advanced solid tumors.
Interventions
- DRUG COM701 in combination with BMS-986207 and nivolumab.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2020-08-31 |
| Est. Completion | 2024-05-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04570839
The ClinicalTrials.gov registry entry for NCT04570839 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Compugen, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which COM701 in combination with BMS-986207 and nivolumab. is the first listed.
NCT04570839 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04570839 about?
NCT04570839 is a clinical study titled "COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.". This is a phase 1/2 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM701 in combination with BMS-986207 and nivolumab in patients with advanced solid tumors.
What is the current status of trial NCT04570839?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2020-08-31. Estimated completion is 2024-05-15.
What interventions are being tested in trial NCT04570839?
The interventions under investigation include: COM701 in combination with BMS-986207 and nivolumab. (DRUG).
Who is sponsoring clinical trial NCT04570839?
This trial is sponsored by Compugen, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.